Education
About Us
Working with TipRanks
Follow Us
BBP - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Products ETF (BBP)
Rating:60Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains over the past three months, indicating improving momentum in its biotech holdings.
Leading Biotech Winners in Top Holdings
Several of the largest positions, such as ImmunityBio and Moderna, have delivered strong year-to-date gains that support the fund’s overall results.
Focused Exposure to Innovative Health Care
With almost all assets in U.S. health care and biotech companies, the fund gives targeted access to a high-innovation segment of the market.
Negative Factors
High Sector Concentration
Nearly all assets are in the health care sector, so the fund is heavily exposed to swings in biotech and pharmaceutical markets.
Limited Geographic Diversification
The ETF invests almost entirely in U.S. companies, offering little protection if the U.S. market or regulatory environment turns negative for biotech.
Relatively High Expense Ratio
The fund charges a higher fee than many broad-market ETFs, which can modestly reduce long-term returns for investors.
BBP vs. SPDR S&P 500 ETF (SPY)
AUM44.87M
RegionNorth America
Expense Ratio0.79%
Beta0.91
IssuerVirtus
Inception DateDec 17, 2014
Dividend YieldN/A
Asset ClassEquity
Index TrackedLifeSci Biotechnology Products Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,422
30 Day Avg. Volume6,437
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
126.40Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering63
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBP Summary
The Virtus LifeSci Biotech Products ETF (BBP) is a fund that follows the LifeSci Biotechnology Products Index, focusing on U.S. biotech companies developing and selling new drugs and medical treatments. It holds a mix of well-known names like Moderna and BioNTech, along with smaller, emerging biotech firms. Investors might consider BBP if they want targeted exposure to the potential growth of cutting-edge medical breakthroughs and to diversify within the health care sector. However, biotech stocks can be very volatile, so the ETF’s price can swing sharply and may go up or down more than the overall market.
How much will it cost me?The Virtus LifeSci Biotech Products ETF (BBP) has an expense ratio of 0.79%, which means you’ll pay $7.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized sector like biotechnology that requires more research and expertise.
What would affect this ETF?The Virtus LifeSci Biotech Products ETF (BBP) could benefit from advancements in biotechnology and increased demand for innovative medical treatments, particularly in the U.S., where it is focused. However, it may face challenges from regulatory hurdles, high research and development costs, or broader economic downturns that could impact funding and growth in the biotech sector.
BBP Top 10 Holdings
BBP is a pure-play U.S. biotech fund, and its story is all about high-risk, high-reward drug developers. Rising names like ImmunityBio, Dynavax, Ardelyx, and Axsome are giving the ETF a helpful lift, as investors warm to their pipelines and recent updates. Moderna and BioNTech, once the pandemic darlings, now look more mixed, no longer powering returns the way they used to. Novavax is still lagging, acting as a bit of a brake. Overall, performance is driven by a concentrated group of mid-cap innovators rather than diversified health care giants.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ImmunityBio | 3.90% | $1.78M | $6.16B | 91.56% | 48 Neutral | |
| Mirum Pharmaceuticals | 2.40% | $1.09M | $5.33B | 113.62% | 56 Neutral | |
| Moderna | 2.17% | $987.03K | $17.22B | 16.42% | 59 Neutral | |
| Dynavax | 2.15% | $980.18K | $1.82B | 19.71% | 70 Outperform | |
| Day One Biopharmaceuticals | 2.06% | $940.09K | $1.18B | -4.72% | 50 Neutral | |
| Amicus | 2.03% | $925.66K | $4.48B | 48.24% | 73 Outperform | |
| Novavax | 1.98% | $903.93K | $1.44B | 3.08% | 47 Neutral | |
| Ardelyx | 1.88% | $857.27K | $1.87B | 47.26% | 55 Neutral | |
| Axsome Therapeutics | 1.88% | $857.09K | $9.29B | 71.51% | 57 Neutral | |
| Halozyme | 1.80% | $817.76K | $8.43B | 32.28% | 73 Outperform |
BBP Technical Analysis
Positive
―
Price Trends
80.07
Positive
76.17
Positive
68.39
Positive
Market Momentum
0.88
Positive
55.22
Neutral
37.03
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 81.84, equal to the 50-day MA of 80.07, and equal to the 200-day MA of 68.39, indicating a bullish trend. The MACD of 0.88 indicates Positive momentum. The RSI at 55.22 is Neutral, neither overbought nor oversold. The STOCH value of 37.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBP.
BBP Peer Comparison
Comparison Results
Performance Comparison
BBP
Virtus LifeSci Biotech Products ETF
82.76
20.54
33.01%
XHS
SPDR S&P Health Care Services ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBC
Virtus LifeSci Biotech Clinical Trials ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents